Loading
Products ordered by how many trial records are linked to them from either side. Top 50 of 1,014 drugs with a value; ties are broken by name. 4,627 of 6,143 trials name at least one product (75%).
| # | Treatment | Trials | Status and modality |
|---|---|---|---|
| 1 | Pembrolizumab | 435 | approved · Antibody |
| 2 | Carboplatin | 390 | approved · Cytotoxic |
| 3 | Cisplatin | 310 | approved · Cytotoxic |
| 4 | Gemcitabine | 294 | approved · Cytotoxic |
| 5 | Capecitabine | 238 | approved · Cytotoxic |
| 6 | Paclitaxel / nab-paclitaxel | 224 | approved · Cytotoxic |
| 7 | Pemetrexed | 178 | approved · Cytotoxic |
| 8 | Bevacizumab | 160 | approved · Antibody |
| 9 | Cyclophosphamide | 159 | approved · Cytotoxic |
| 10 | Docetaxel | 156 | approved · Cytotoxic |
| 11 | FOLFOX (5-FU, leucovorin, oxaliplatin) | 153 | standard-of-care · Cytotoxic |
| 12 | Nivolumab | 152 | approved · Antibody |
| 13 | Durvalumab | 141 | approved · Antibody |
| 14 | Fluorouracil (5-FU) | 140 | approved · Cytotoxic |
| 15 | Doxorubicin | 126 | approved · Cytotoxic |
| 16 | Oxaliplatin | 108 | approved · Cytotoxic |
| 17 | CAPOX (capecitabine, oxaliplatin) | 103 | standard-of-care · Cytotoxic |
| 18 | Nab-paclitaxel | 103 | approved · Cytotoxic |
| 19 | Rituximab | 103 | approved · Antibody |
| 20 | Atezolizumab | 102 | approved · Antibody |
| 21 | Dexamethasone | 99 | approved · Hormonal |
| 22 | Cetuximab | 97 | approved · Antibody |
| 23 | Etoposide | 90 | approved · Cytotoxic |
| 24 | Trastuzumab | 89 | approved · Antibody |
| 25 | Prednisone | 88 | approved · Hormonal |
| 26 | Bevacizumab (glioblastoma use) | 82 | approved · Antibody |
| 27 | Adebrelimab | 78 | approved · Antibody |
| 28 | Tislelizumab | 78 | approved · Antibody |
| 29 | FOLFIRI (5-FU, leucovorin, irinotecan) | 76 | standard-of-care · Cytotoxic |
| 30 | Toripalimab | 72 | approved · Antibody |
| 31 | Osimertinib | 67 | approved · Small molecule |
| 32 | Vincristine | 67 | approved · Cytotoxic |
| 33 | Olaparib | 64 | approved · Small molecule |
| 34 | Fulvestrant | 63 | approved · Hormonal |
| 35 | Ipilimumab | 61 | approved · Antibody |
| 36 | Lenalidomide | 61 | approved · Degrader |
| 37 | Venetoclax | 60 | approved · Small molecule |
| 38 | Cemiplimab | 58 | approved · Antibody |
| 39 | Ivonescimab | 58 | approved · Bispecific or engager |
| 40 | Sintilimab | 57 | approved · Antibody |
| 41 | Sacituzumab tirumotecan | 54 | approved · Antibody-drug conjugate |
| 42 | Temozolomide | 54 | standard-of-care · Cytotoxic |
| 43 | Lenvatinib | 53 | approved · Small molecule |
| 44 | Trastuzumab deruxtecan | 52 | approved · Antibody-drug conjugate |
| 45 | Fludarabine | 49 | approved · Cytotoxic |
| 46 | Sacituzumab govitecan | 49 | approved · Antibody-drug conjugate |
| 47 | Azacitidine | 46 | approved · Cytotoxic |
| 48 | Pertuzumab | 46 | approved · Antibody |
| 49 | Enzalutamide | 45 | approved · Hormonal |
| 50 | Abiraterone acetate | 39 | approved · Hormonal |
964 more drugs have a value below the top 50; the full list of drugs is at /drugs/.
Counts distinct trial records that either name the product in their drugs field or are named in the product's trials field. The context column gives the product's status and modality group. Supportive care medicines (antiemetics, growth factors, epoetins, bone-modifying agents, antidotes, opioids for cancer pain, immunoglobulin; drug records flagged supportive) are not products or treatments here and are left out.
Coverage. 4,627 of 6,143 trials name at least one product (75%). Rows with a value of zero are not listed. Nothing is weighted, imputed or averaged; the ordering is by the number shown, then by name.
Machine-readable copy: /rankings/drugs-by-trials/data.json. Registry: src/lib/rankings.ts.